InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2026-03-03 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2025-12-11 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2025-10-09 | Gilbert Cisneros(D-CA31) | house | Sale | $1,001 - $15,000 |
| 2025-03-24 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2022-12-23 | Josh Gottheimer(D-NJ05) | house | Sale | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total revenues | $39.4M+63.4% | $24.1M-28.2% | $33.6M+88.6% | $17.8M+45.1% | $12.3M |
| Cost of revenues | $74.6M-4.3% | $77.9M-7.0% | $83.8M | — | — |
| Research and development | $106.2M-2.4% | $108.8M+18.8% | $91.6M+22.9% | $74.6M-17.6% | $90.5M |
| Selling, general and administrative | $485.6M+51.0% | $321.6M-4.4% | $336.4M-10.8% | $377.2M+23.8% | $304.8M |
| Amortization of intangible assets | $89.5M+14.7% | $78.0M-5.4% | $82.4M-0.3% | $82.6M+175.5% | $30.0M |
| Intangible asset impairment charges | $0 | $0-100.0% | $20.2M | $0 | — |
| Contingent consideration loss (gain) | $25.4M+516.0% | -$6.1M-302.8% | -$1.5M | — | — |
| Total costs and expenses | $781.2M+34.7% | $580.2M-5.3% | $612.8M-1.3% | $621.1M+25.8% | $493.7M |
| Operating earnings (loss) | -$62.3M-176.3% | $81.7M+1649.9% | -$5.3M-111.4% | $46.1M-46.4% | $86.0M |
| Interest and other income, net | $13.3M-18.2% | $16.2M+55.0% | $10.5M-51.8% | $21.7M+105.2% | $10.6M |
| Interest expense | $0 | $0+100.0% | -$2.4M+65.8% | -$7.1M+69.8% | -$23.4M |
| Total other income (expense), net | $13.3M-18.2% | $16.2M+101.6% | $8.0M-45.0% | $14.6M | — |
| Earnings (loss) before income taxes | -$49.0M-150.1% | $97.9M+3434.5% | $2.8M | — | — |
| Income tax expense (benefit) | -$10.5M-143.7% | $24.0M+1552.1% | $1.5M | — | — |
| Net earnings (loss) | -$38.5M-152.2% | $73.9M+5512.8% | $1.3M | — | — |
| Basic (in dollars per share) | -$680-150.7% | $1K+6600.0% | $20-98.2% | $1K+11.9% | $1K |
| Diluted (in dollars per share) | -$680-151.5% | $1K+6500.0% | $20-98.1% | $1K+6.1% | $980 |
| Basic (in shares) | $56.45B+2.5% | $55.10B+1.0% | $54.54B+1.6% | $53.67B+1.1% | $53.10B |
| Diluted (in shares) | $56.45B+0.9% | $55.96B+0.8% | $55.51B-10.0% | $61.68B+13.5% | $54.36B |
| Net product sales | |||||
| Total revenues | $39.4M+63.4% | $24.1M-28.2% | $33.6M+88.6% | $17.8M+45.1% | $12.3M |
| Collaboration revenue (ZURZUVAE) | |||||
| Total revenues | $39.4M+63.4% | $24.1M-28.2% | $33.6M+88.6% | $17.8M+45.1% | $12.3M |
| Royalty, licensing, and other revenues | |||||
| Total revenues | $39.4M+63.4% | $24.1M-28.2% | $33.6M+88.6% | $17.8M+45.1% | $12.3M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Supernus Pharmaceuticals Q1 2026 Earnings Preview
Supernus Pharmaceuticals Earnings: What To Look For From SUPN
Branded Pharmaceuticals Stocks Q4 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?